Northern, WI 7/20/12 (StreetBeat) – Onyx (Nasdaq: ONXX) shares hit a 52 week high in trading Friday after announcing that its competitor’s drug trials failed to demonstrate statistically significant results on the study. Bristol-Meyers (NYSE: BMY) reported last night that its brivanib, a liver cancer treatment, failed to meet its primary overall survival objective in a Phase III Trial. Onyx’s Nexavar is used to treat liver cancer, and CEO Leerink Swann wrote that brivanib’s failure represents a significant positive for the long-term outlook of Nexavar. Onyx increased 6% in morning trade Friday, up $4.10 to $72.50. Bristol Meyers decreased 1.75% to $35.51 after reporting these results.
Please contact www.thestreetbeat.com for interest in our latest investor relations platform the “CEO Interview Series” with its host Steve Kanaval. The package includes a one-on-one interview with a seasoned industry professional; published segment to our web site with embedded audio/video file; and a compressed file that can be easily e-mailed out to your current and/or potential investors. Please e-mail bflautt@gmail.com or call (662) 392-0740 for pricing and scheduling.
StreetBeat Disclaimer
No comments:
Post a Comment